Chemomab Therapeutics (CMMB) Earnings Date, Estimates & Call Transcripts $1.13 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.12 0.00 (-0.44%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Chemomab Therapeutics Earnings Summary Chemomab Therapeutics released Q1 2025 earnings on May 15, 2025, reporting an EPS of -$0.14, which topped the consensus estimate of -$0.20 by $0.06. With a trailing EPS of -$0.76, Chemomab Therapeutics' earnings are expected to grow next year, from ($1.00) to ($0.70) per share. Upcoming Q2 Earnings DateAug. 20Before Market OpensEstimatedConsensus EPS (May. 15) -$0.20 Actual EPS (May. 15) -$0.14 Beat By $0.06 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K)CMMB Upcoming EarningsChemomab Therapeutics' next earnings date is estimated for Wednesday, August 20, 2025, based on past reporting schedules. Powered by Get Chemomab Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCMMB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Chemomab Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.20-$0.20-$0.20Q2 20251-$0.20-$0.20-$0.20Q3 20251-$0.20-$0.20-$0.20Q4 20251-$0.20-$0.20-$0.20 Chemomab Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/20/2025(Estimated)--------5/15/2025Q1 2025-$0.20-$0.14+$0.06-$0.14--8/21/2024Q2 2024-$0.20-$0.26 -$0.06-$0.26--5/9/2024Q1 2024-$0.20-$0.28 -$0.08-$0.28--3/7/2024Q4 2023-$0.40-$0.26+$0.14-$0.26--11/9/2023Q3 2023-$0.60-$0.34+$0.26-$0.34--8/14/2023Q2 2023-$0.80-$0.72+$0.08-$0.72-- Chemomab Therapeutics Earnings - Frequently Asked Questions When is Chemomab Therapeutics' earnings date? Chemomab Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 20th, 2025 based off last year's report dates. Learn more on CMMB's earnings history. Did Chemomab Therapeutics beat their earnings estimates last quarter? In the previous quarter, Chemomab Therapeutics (NASDAQ:CMMB) reported ($0.14) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.20) by $0.06. Learn more on analysts' earnings estimate vs. CMMB's actual earnings. How much profit does Chemomab Therapeutics generate each year? Chemomab Therapeutics (NASDAQ:CMMB) has a recorded net income of -$13.94 million. CMMB has generated -$0.76 earnings per share over the last four quarters. What is Chemomab Therapeutics' EPS forecast for next year? Chemomab Therapeutics' earnings are expected to grow from ($1.00) per share to ($0.70) per share in the next year. More Earnings Resources from MarketBeat Related Companies Oncolytics Biotech Earnings Climb Bio Earnings Elutia Earnings Entera Bio Earnings TScan Therapeutics Earnings eXoZymes Earnings Cabaletta Bio Earnings IGM Biosciences Earnings Pliant Therapeutics Earnings Zura Bio Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report This page (NASDAQ:CMMB) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
